Alector Inc Q2 2023 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Myles Robert Minter - William Blair & Company L.L.C., Research Division - Analyst : Just on the INFRONT-3 analysis here, just on a blinded basis, are you seeing the same variability on a symptomatic patient population as what you saw or what they saw in GENFI2, specifically looking at the analysis that you did with the N=12 INFRONT-2 patient population versus the 10 patients you picked from GENFI2? Like is it that sort of level of variability that we should be looking at that you're seeing on a blinded basis in INFRONT-3?

Question: Myles Robert Minter - William Blair & Company L.L.C., Research Division - Analyst : So you'd caution against extrapolating that and saying that in the placebo arm, patients are going to decline like 12 points on CDR on placebo over 2 years.

Question: Myles Robert Minter - William Blair & Company L.L.C., Research Division - Analyst : Okay. A quick one on INVOKE-2. Were there any patients that were positive or potentially positive for cerebral amyloid angiopathy that may have implanted those been [RUF] signals.